302 related articles for article (PubMed ID: 8978584)
1. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis.
Pectasides D; Mylonakis A; Varthalitis J; Kostopoulou M; Constantinou A; Papazachariou K; Antoniou F; Dimitriadis M; Athanassiou A
Oncology; 1997; 54(1):1-6. PubMed ID: 8978584
[TBL] [Abstract][Full Text] [Related]
2. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
3. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
[TBL] [Abstract][Full Text] [Related]
4. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy.
Ahn MJ; Lee JS; Lee KH; Suh C; Choi SS; Kim SH
Am J Clin Oncol; 1994 Apr; 17(2):150-6. PubMed ID: 8141107
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
7. Prevention of acute and delayed cisplatin-induced nausea and vomiting with intravenous ondansetron plus intravenous dexamethasone.
Liaw CC; Wang CH; Chang HK; Kao CY; Huang JS
Chang Gung Med J; 2000 Jul; 23(7):413-9. PubMed ID: 10974756
[TBL] [Abstract][Full Text] [Related]
8. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
Tanimura S; Banba J; Tomoyasu H; Masaki M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
[TBL] [Abstract][Full Text] [Related]
9. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).
Joss RA; Bacchi M; Buser K; Kirchner V; Neuenschwander H; Orth B; Aapro MS; Thürlimann B
Ann Oncol; 1994 Mar; 5(3):253-8. PubMed ID: 8186174
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
11. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
Chen PT; Liaw CC
Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417
[TBL] [Abstract][Full Text] [Related]
12. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy.
White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C
Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, double-blind comparison of i.v. and oral administration of ondansetron plus dexamethasone for acute cisplatin-induced emesis. Ondansetron Acute Emesis Study Group.
Krzakowski M; Graham E; Goedhals L; Joly F; Pawlicki M; Rapoport B; Yelle L; Lees J; McQuade B
Anticancer Drugs; 1998 Aug; 9(7):593-8. PubMed ID: 9773802
[TBL] [Abstract][Full Text] [Related]
14. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
Roila F
Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
[TBL] [Abstract][Full Text] [Related]
15. Oral ondansetron and intravenous dexamethasone in the prevention of cisplatin-induced emesis. A phase II trial in women.
Franchi M; Donadello N; Zanaboni F; Tusei A; Scorbati E
Oncology; 1995; 52(6):509-12. PubMed ID: 7478441
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice.
Ithimakin S; Runglodvatana K; Nimmannit A; Akewanlop C; Srimuninnimit V; Keerativitayanan N; Soparattanapaisarn N; Laocharoenkeat A
Support Care Cancer; 2012 Apr; 20(4):849-55. PubMed ID: 21505898
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.
Italian Group for Antiemetic Research
N Engl J Med; 2000 May; 342(21):1554-9. PubMed ID: 10824073
[TBL] [Abstract][Full Text] [Related]
18. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
[TBL] [Abstract][Full Text] [Related]
20. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
